Pharmogenetic testing can increase your quality score while reducing your costs. The national average for readmissions is 23% with a majority of patients returning from a post-acute care setting. This is a lose/lose scenario for both the hospital and the sub-acute provider, costing both in bottom line revenue.
Reducing readmissions can often be accomplished by customizing a patient's medication to the way their individual body metabolizes medications. This decreases the amount of time it takes them to become therapeutic as well as reducing the overall occurrences of Adverse Drug Events (ADE), the leading cause of readmissions.
(844) 794.3637 EXT 800
Increase your bottom line
While the ideal is to test all patients, this is likely to be impractical. The portion of your census considered to be high-risk and that can yield results related to your CQM is a good starting point.
CMS has mandated a 30% reduction in off label use of antipsychotics in the post-acute care environment. The trial and error process of prescribing different antipsychotic medications, in search of the one that works best, often skews your CQM in the wrong direction, as each change in Rx increases the number of occurrences.
This segment of your resident population is typically the largest user of medications. Pharmacogenetic testing may reduce your overall medication expense.
Expensive medications increase your average daily expense. Targeting the more expensive drugs and the cost of an appropriate lower dose or potential alternate therapies can help your bottom line. Pharmacogenetic testing will tell you what your options are on a case by case basis.
Drugs can be broken down too quickly or improperly, requiring a higher dosage or change in medication in many cases.
Drugs are not metabolized fast enough resulting in either too little or too much of the drug in the body.
Drugs, supplements and some foods will reduce or increase the effectiveness of the medication.